2 results
Approved WMOCompleted
Cohort 1 (HER2-positive/amplified MBC): MCLA-128 + trastuzumab ± vinorelbine Primary objective:• Evaluate efficacy of MCLA-128 combined with trastuzumab ± vinorelbine in terms of clinical benefit rate (CBR) at 24 weeks based on RECIST 1.1 (per…
Approved WMORecruiting
The primary objective is to investigate the validity of the volumes measured by the Hexoskin shirt relative to a (mobile) spirometer in healthy subjects and in COPD patients. Secondary objective are to determine reliability of the Hexoskin shirt…